Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000666724 | SCV000791071 | likely pathogenic | Peroxisome biogenesis disorder type 3B; Peroxisome biogenesis disorder 3A (Zellweger) | 2017-04-24 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004547837 | SCV004111403 | likely pathogenic | PEX12-related disorder | 2023-05-25 | criteria provided, single submitter | clinical testing | The PEX12 c.460C>T variant is predicted to result in premature protein termination (p.Arg154*). This variant was reported in an individual with peroxisome biogenesis disorder 3 (Ebberink et al. 2011. PubMed ID: 21031596). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Nonsense variants in PEX12 are expected to be pathogenic. This variant is interpreted as likely pathogenic. |
Labcorp Genetics |
RCV003534546 | SCV004297756 | pathogenic | Peroxisome biogenesis disorder 3A (Zellweger) | 2023-01-22 | criteria provided, single submitter | clinical testing | This premature translational stop signal has been observed in individual(s) with Zellweger syndrome spectrum (PMID: 21031596). This sequence change creates a premature translational stop signal (p.Arg154*) in the PEX12 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PEX12 are known to be pathogenic (PMID: 9090384, 9632816, 21031596). This variant is not present in population databases (gnomAD no frequency). ClinVar contains an entry for this variant (Variation ID: 551612). For these reasons, this variant has been classified as Pathogenic. |